From Oncology to Neuroscience, PGx Growing in Scope at Pfizer | GenomeWeb

NEW YORK (GenomeWeb) – The perfect drug molecule, according to Pfizer's Jean-Claude Marshall, is one that is right on target, has no off-target effects, and is highly bioavailable. Importantly, it is metabolized by a range of enzymes but not dependent on those really buggy ones, like CYP2D6, that can be variable.

"No drug is going to be that. We know that right up front," Marshall, director of Pfizer's Clinical Pharmacogenomics Lab, told GenomeWeb last week. "It's just our goal to attain that."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.